Smithwood Advisers’s AstraZeneca AZN Stock Holding History

Smithwood Advisers’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-748,200	Closed	-$52.7M	–	21
2014 Q4	$52.7M	Sell	748,200 -1,800	-0.2%	-$129K	6.47%	8
2014 Q3	$53.6M	Buy	750,000 +100,000	+15%	+$7.32M	3.44%	12
2014 Q2	$48.3M	Buy	+650,000	New	+$47M	3.45%	11

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

MAA

Managed Account Advisors Jersey City, New Jersey $121B AUM 7.42% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 28.54% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Smithwood Advisers's AZN Position: Q1 2015 in Review

Smithwood Advisers sold out of AstraZeneca (AZN) in Q1 2015, closing a stake of 748,200 shares — an estimated $52.7M sold.

Smithwood Advisers first reported a position in AZN in Q2 2014 and held it in 3 quarters. The position peaked at $53.6M in Q3 2014. 386 funds tracked by Wall St. Rank hold AZN as of Q1 2015.

Smithwood Advisers reported no remaining AstraZeneca position as of Q1 2015 after selling out during the quarter.
Smithwood Advisers sold 748,200 AstraZeneca shares in Q1 2015, an estimated $52.7M.
Smithwood Advisers first reported a position in AstraZeneca in Q2 2014 and held it in 3 quarters.
Smithwood Advisers's AstraZeneca position peaked at $53.6M in Q3 2014.
386 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2015.

Based on Smithwood Advisers's 13F filing for Q1 2015, filed 15 May 2015.